Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Treasury Shares (2021 - 2025)

Verrica Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $10514.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $10514.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $10514.0 (changed 0.0% YoY), and the annual figure for FY2025 was $10514.0, changed 0.0%.
  • Treasury Shares for Q4 2025 was $10514.0 at Verrica Pharmaceuticals, down from $25000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for VRCA hit a ceiling of $475000.0 in Q2 2021 and a floor of $10514.0 in Q1 2024.
  • Median Treasury Shares over the past 5 years was $105144.0 (2021), compared with a mean of $164023.4.
  • Biggest five-year swings in Treasury Shares: soared 304.21% in 2022 and later tumbled 90.0% in 2024.
  • Verrica Pharmaceuticals' Treasury Shares stood at $105144.0 in 2021, then soared by 304.21% to $425000.0 in 2022, then plummeted by 86.79% to $56150.0 in 2023, then crashed by 81.28% to $10514.0 in 2024, then changed by 0.0% to $10514.0 in 2025.
  • The last three reported values for Treasury Shares were $10514.0 (Q4 2025), $25000.0 (Q3 2025), and $10514.0 (Q2 2025) per Business Quant data.